Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report

Table 1 Association between CMV viral load and ganciclovir TDM analysis

Days of life	Weeks of postmenstrual age	Weight (g)	Serum creatinine (mg/dl)	Ganciclovir therapy		Ganciclovir TDM			CMV load^d (copies/ml)
Days of life	Weeks of postmenstrual age	Weight (g)	Serum creatinine (mg/dl)	Dose (mg/kg)	Interval (hour)	Peak level^a (mg/l)	Trough level^b (mg/l)	Estimated AUC_0–12^c (mg ▪ h/l)	CMV load^d (copies/ml)
48	30 + 6	1132	0.39	Reference (pre-therapy)					5.0 × 10⁶
55	31 + 6	1296	0.32	5	12	6.0	3.5	53.9	5.3 × 10⁴
70	34 + 0	1120	0.26	5	24	6.0	0.3	19.2	1.6 × 10⁵
84	36 + 0	1326	0.27	5	12	4.2	1.1	31.8	2.4 × 10³
107	39 + 2	2058	0.32	22 days post-therapy					1.0 × 10⁶

CMV cytomegalovirus, TDM therapeutic drug monitoring, AUC area under the concentration-time curve
^aThe peak levels of ganciclovir were measured at 90 min after ganciclovir infusion
^bThe trough levels of ganciclovir were measured at 11 h after ganciclovir infusion
^cThe estimated values of AUC_0–12 were calculated using Trapezoidal rule
^dCMV loads in the peripheral blood were determined by real-time PCR

ISSN: 1471-2431